Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456674 · ClinicalTrials.gov registry record · NA
LaseMD System for the Treatment of Melasma
A NA study of Melasma, sponsored by CynosureLutronic.
- Active
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03456674: Active NA study of Melasma, sponsored by CynosureLutronic.
NCT03456674 is a NA study of Melasma that is active but no longer recruiting, run by CynosureLutronic. The registered enrollment target is 10 participants, below the 44-participant average among 8 other Melasma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03456674, a NA study of Melasma, is active but no longer recruiting, sponsored by CynosureLutronic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.
Primary Outcome
A change in MASI score from baseline to post-treatment. The MASI quantifies the pigmentation area, darkness, and homogeneity, assessing four areas of the face for hyperpigmentation: forehead, right malar region, left malar region and chin, corresponding to 30%, 30%, 30% and 10% of the total face. The melasma area in each region is given a numeric value from 1 (\<10%) to 6 (90-100%) in each of the four regions. Darkness of pigment is compared to normal skin in each area on a scale of 0 (absent) t
Conditions Studied
Interventions
- DEVICE LaseMD System
Study Locations (1)
New York
- Laser and Skin Surgery Center of New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2019-06-30 |
| Phase | NA |
What the registry record for NCT03456674 still lists
NCT03456674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 44-participant average among 8 other Melasma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which LaseMD System is the first listed.
NCT03456674 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03456674 about?
NCT03456674 is a clinical study titled "LaseMD System for the Treatment of Melasma". This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.
What is the current status of trial NCT03456674?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2018-02-07. Estimated completion is 2019-06-30.
What conditions does trial NCT03456674 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT03456674?
The interventions under investigation include: LaseMD System (DEVICE).
Who is sponsoring clinical trial NCT03456674?
This trial is sponsored by CynosureLutronic, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03456674 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03456674's enrollment target sits among peer trials
10 8th of 8 higher than 1 of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI